Small molecule modulation of p75NTR engages the autophagy-lysosomal pathway and reduces huntingtin aggregates in cellular and mouse models of Huntington's disease

Huntington's disease (HD) is a neurodegenerative disorder caused by a CAG repeat expansion in the HTT gene encoding a mutant huntingtin (mHtt) protein. mHtt aggregates within neurons causing degeneration primarily in the striatum. There is currently a need for disease-modifying treatments for H...

Full description

Saved in:
Bibliographic Details
Main Authors: Danielle A. Simmons, Namitha Alexander, Gloria Cao, Ido Rippin, Yarine Lugassy, Hagit Eldar-Finkelman, Frank M. Longo
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:Neurotherapeutics
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S187874792400182X
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850239967846989824
author Danielle A. Simmons
Namitha Alexander
Gloria Cao
Ido Rippin
Yarine Lugassy
Hagit Eldar-Finkelman
Frank M. Longo
author_facet Danielle A. Simmons
Namitha Alexander
Gloria Cao
Ido Rippin
Yarine Lugassy
Hagit Eldar-Finkelman
Frank M. Longo
author_sort Danielle A. Simmons
collection DOAJ
description Huntington's disease (HD) is a neurodegenerative disorder caused by a CAG repeat expansion in the HTT gene encoding a mutant huntingtin (mHtt) protein. mHtt aggregates within neurons causing degeneration primarily in the striatum. There is currently a need for disease-modifying treatments for HD. Many therapeutic studies have focused on lowering mHtt levels by reducing its production or enhancing its clearance. One way to clear mHtt aggregates is to promote autophagy, which is disrupted in HD. Our previous studies showed that the small molecule p75 neurotrophin receptor (p75NTR) ligand, LM11A-31, prevented HD-related neuropathologies and behavioral deficits in multiple HD mouse models. This study investigated whether modulating p75NTR with LM11A-31, would reduce mHtt aggregates via autophagic/lysosomal mechanisms in HD models. LM11A-31 decreased mHtt aggregates in human neuroblastoma SH-SY5Y cells expressing mHtt (exon 1 with 74 CAG repeats) and in the striatum of R6/2 and zQ175dn mouse models of HD. The LM11A-31 associated decrease in mHtt aggregates in vitro was accompanied by increased autophagic/lysosomal activity as indicated by altered levels of relevant markers including p62/SQSTM1 and the lysosomal protease, mature cathepsin D, and increased autophagy flux. In R6/2 and/or zQ175dn striatum, LM11A-31 increased AMPK activation, normalized p62/SQSTM1 and LC3II levels, and enhanced LAMP1 and decreased LC3B association with mHtt. Thus, LM11A-31 reduces mHtt aggregates and may do so via engaging autophagy/lysosomal systems. LM11A-31 has successfully completed a Phase 2a clinical trial for mild-to-moderate Alzheimer's disease and our results here strengthen its potential as a candidate for HD clinical testing.
format Article
id doaj-art-e1420c3fab5b4ce1b0e9056e4b943fd5
institution OA Journals
issn 1878-7479
language English
publishDate 2025-03-01
publisher Elsevier
record_format Article
series Neurotherapeutics
spelling doaj-art-e1420c3fab5b4ce1b0e9056e4b943fd52025-08-20T02:01:00ZengElsevierNeurotherapeutics1878-74792025-03-01222e0049510.1016/j.neurot.2024.e00495Small molecule modulation of p75NTR engages the autophagy-lysosomal pathway and reduces huntingtin aggregates in cellular and mouse models of Huntington's diseaseDanielle A. Simmons0Namitha Alexander1Gloria Cao2Ido Rippin3Yarine Lugassy4Hagit Eldar-Finkelman5Frank M. Longo6Department of Neurology & Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA; Corresponding author.Department of Neurology & Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USADepartment of Neurology & Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USADepartment of Human Molecular Genetics & Biochemistry, Faculty of Medicine and Health Sciences, Tel Aviv University, IsraelDepartment of Human Molecular Genetics & Biochemistry, Faculty of Medicine and Health Sciences, Tel Aviv University, IsraelDepartment of Human Molecular Genetics & Biochemistry, Faculty of Medicine and Health Sciences, Tel Aviv University, IsraelDepartment of Neurology & Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA; Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USAHuntington's disease (HD) is a neurodegenerative disorder caused by a CAG repeat expansion in the HTT gene encoding a mutant huntingtin (mHtt) protein. mHtt aggregates within neurons causing degeneration primarily in the striatum. There is currently a need for disease-modifying treatments for HD. Many therapeutic studies have focused on lowering mHtt levels by reducing its production or enhancing its clearance. One way to clear mHtt aggregates is to promote autophagy, which is disrupted in HD. Our previous studies showed that the small molecule p75 neurotrophin receptor (p75NTR) ligand, LM11A-31, prevented HD-related neuropathologies and behavioral deficits in multiple HD mouse models. This study investigated whether modulating p75NTR with LM11A-31, would reduce mHtt aggregates via autophagic/lysosomal mechanisms in HD models. LM11A-31 decreased mHtt aggregates in human neuroblastoma SH-SY5Y cells expressing mHtt (exon 1 with 74 CAG repeats) and in the striatum of R6/2 and zQ175dn mouse models of HD. The LM11A-31 associated decrease in mHtt aggregates in vitro was accompanied by increased autophagic/lysosomal activity as indicated by altered levels of relevant markers including p62/SQSTM1 and the lysosomal protease, mature cathepsin D, and increased autophagy flux. In R6/2 and/or zQ175dn striatum, LM11A-31 increased AMPK activation, normalized p62/SQSTM1 and LC3II levels, and enhanced LAMP1 and decreased LC3B association with mHtt. Thus, LM11A-31 reduces mHtt aggregates and may do so via engaging autophagy/lysosomal systems. LM11A-31 has successfully completed a Phase 2a clinical trial for mild-to-moderate Alzheimer's disease and our results here strengthen its potential as a candidate for HD clinical testing.http://www.sciencedirect.com/science/article/pii/S187874792400182XNeurotrophinHuntingtin inclusionsNeurodegenerationAutophagyp75NTR
spellingShingle Danielle A. Simmons
Namitha Alexander
Gloria Cao
Ido Rippin
Yarine Lugassy
Hagit Eldar-Finkelman
Frank M. Longo
Small molecule modulation of p75NTR engages the autophagy-lysosomal pathway and reduces huntingtin aggregates in cellular and mouse models of Huntington's disease
Neurotherapeutics
Neurotrophin
Huntingtin inclusions
Neurodegeneration
Autophagy
p75NTR
title Small molecule modulation of p75NTR engages the autophagy-lysosomal pathway and reduces huntingtin aggregates in cellular and mouse models of Huntington's disease
title_full Small molecule modulation of p75NTR engages the autophagy-lysosomal pathway and reduces huntingtin aggregates in cellular and mouse models of Huntington's disease
title_fullStr Small molecule modulation of p75NTR engages the autophagy-lysosomal pathway and reduces huntingtin aggregates in cellular and mouse models of Huntington's disease
title_full_unstemmed Small molecule modulation of p75NTR engages the autophagy-lysosomal pathway and reduces huntingtin aggregates in cellular and mouse models of Huntington's disease
title_short Small molecule modulation of p75NTR engages the autophagy-lysosomal pathway and reduces huntingtin aggregates in cellular and mouse models of Huntington's disease
title_sort small molecule modulation of p75ntr engages the autophagy lysosomal pathway and reduces huntingtin aggregates in cellular and mouse models of huntington s disease
topic Neurotrophin
Huntingtin inclusions
Neurodegeneration
Autophagy
p75NTR
url http://www.sciencedirect.com/science/article/pii/S187874792400182X
work_keys_str_mv AT danielleasimmons smallmoleculemodulationofp75ntrengagestheautophagylysosomalpathwayandreduceshuntingtinaggregatesincellularandmousemodelsofhuntingtonsdisease
AT namithaalexander smallmoleculemodulationofp75ntrengagestheautophagylysosomalpathwayandreduceshuntingtinaggregatesincellularandmousemodelsofhuntingtonsdisease
AT gloriacao smallmoleculemodulationofp75ntrengagestheautophagylysosomalpathwayandreduceshuntingtinaggregatesincellularandmousemodelsofhuntingtonsdisease
AT idorippin smallmoleculemodulationofp75ntrengagestheautophagylysosomalpathwayandreduceshuntingtinaggregatesincellularandmousemodelsofhuntingtonsdisease
AT yarinelugassy smallmoleculemodulationofp75ntrengagestheautophagylysosomalpathwayandreduceshuntingtinaggregatesincellularandmousemodelsofhuntingtonsdisease
AT hagiteldarfinkelman smallmoleculemodulationofp75ntrengagestheautophagylysosomalpathwayandreduceshuntingtinaggregatesincellularandmousemodelsofhuntingtonsdisease
AT frankmlongo smallmoleculemodulationofp75ntrengagestheautophagylysosomalpathwayandreduceshuntingtinaggregatesincellularandmousemodelsofhuntingtonsdisease